Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TLR7/8/9 antagonist 2 is an orally active and highly bioavailable vTLR7/8/9 antagonist. TLR7/8/9 antagonist 2 inhibits HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50s of 0.011 μM, 0.029 μM and 0,052 μM, respectively. TLR7/8/9 antagonist 2 can be used to study auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis.
Description | TLR7/8/9 antagonist 2 is an orally active and highly bioavailable vTLR7/8/9 antagonist. TLR7/8/9 antagonist 2 inhibits HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50s of 0.011 μM, 0.029 μM and 0,052 μM, respectively. TLR7/8/9 antagonist 2 can be used to study auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis. |
Targets&IC50 | HEK/hTLR7:0.011 μM, HEK/hTLR8:0.029 μM, HEK/hTLR9:0.052 μM |
In vitro |
TLR7/8/9 antagonist 2 exhibited inhibitory activity against HEK/hTLR7, HEK/hTLR8, and HEK/hTLR9 with IC50 values of 0.011 μM, 0.029 μM, and 0,052 μM, respectively.[1] TLR7/8/9 antagonist 2 showed inhibitory activity against hPBMC/TLR9 with an IC50 value of 420 nM.[1] |
In vivo | TLR7/8/9 antagonist 2 has a high in vivo bioavailability.[1] |
Molecular Weight | 405.54 |
Formula | C23H31N7 |
CAS No. | 2920729-91-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TLR7/8/9 antagonist 2 2920729-91-3 Immunology/Inflammation TLR TLR7/8/9antagonist2 inhibitor inhibit